# Innovent Biologics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/innovent-biologics

- Industry: Pharmaceuticals
- Headquarters: Suzhou, China
- Website: www.innoventbio.com
- Total disclosed funding: $545M
- Latest round: Series E (Apr 26, 2018)
- Investors on record: 17

## About

Established in 2011 and based in Suzhou, China, Innovent Biologics, Inc. is a biopharmaceutical company that engages in the development, manufacturing, and commercialization of new drugs for cancers. In October 2018, it was listed on the Hong Kong Stock Exchange under the number 01801. In December 2024, Innovent Biologics, Inc. raised an undisclosed amount of venture funding from new investor Xuhui Science and Technology Venture Capital. It has multiple branches in Suzhou, Shanghai, Beijing, and overseas USA and Europe. Innovent Biologics, Inc. provides 35 monoclonal antibody drugs for cancer, immunity, and metabolic disease. It has eight products that were approved for marketing, and its product trademarks include TYVYT®, BYVASDA®, SULINNO®, HALPRYZA®, EMAZYRE®, and CYRAMZA®. It has 3 drugs in the NMPA review phase, 5 drugs are in the three-phase clinical trials, and the other 19 new drugs are in clinical research and development. Innovent Biologics, Inc. plans to promote lung cancer drugs IBI-351 (KRASG12C) and IBI-344 (ROS1/TRK) clinical registration and submit a new drug application (NDA) by the end of 2023. ADC molecular drugs will enter into the first phase of clinical trials. Besides, it also focuses on the fields of cardiovascular and metabolic, autoimmune, and ophthalmology. And obesity diabetes drug IBI-362, Tao drug IBI-311 will be in the third phase of registration clinical, and gout drug IBI-128 will be in the third phase of clinical trials by the end of 2023.

## Funding rounds

- Series E, Apr 26, 2018, $150M — Capital Group Private Markets, Temasek Holdings, Taikang Asset Management, Legend Capital, Lilly Asia Ventures, Hillhouse Investment, Rock Springs Capital, Cormorant Asset Management, Ally Bridge Group
- Series D, Nov 29, 2016, $260M — Temasek Holdings, Taikang Asset Management, Legend Capital, Ping An Insurance Group, Hillhouse Investment, CS Capital, Milestone Asset Management, China Life Capital
- Series C, Jan 22, 2015, $100M — Temasek Holdings, Legend Capital, Eight Roads Ventures, Lilly Asia Ventures, Frontline BioVentures
- Series B, Jun 16, 2012, $30M — Eight Roads Ventures, F-Prime Capital, Lilly Asia Ventures
- Series A, Oct 12, 2011, $5M — Eight Roads Ventures
- Angel, Aug 1, 2011 — Oriza Holdings, Frontline BioVentures

## Investors

- Oriza Holdings (https://capitalatlas.ai/funds/oriza-holdings) — Angel
- Frontline BioVentures (https://capitalatlas.ai/funds/frontline-bioventures) — Angel, Series C
- Eight Roads Ventures (https://capitalatlas.ai/funds/eight-roads-ventures) — Series A, Series B, Series C
- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series B
- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series B, Series C, Series E
- Temasek Holdings — Series C, Series D, Series E
- Legend Capital — Series C, Series D, Series E
- Taikang Asset Management — Series D, Series E
- Ping An Insurance Group — Series D
- Hillhouse Investment (https://capitalatlas.ai/funds/hillhouse-investment) — Series D, Series E
- CS Capital — Series D
- Milestone Asset Management — Series D
- China Life Capital — Series D
- Capital Group Private Markets (https://capitalatlas.ai/funds/capital-group-private-markets) — Series E
- Rock Springs Capital — Series E
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series E
- Ally Bridge Group (https://capitalatlas.ai/funds/ally-bridge-group) — Series E